Blockade of alternative T cell checkpoint molecules, such as Tim3, is a promising alternative to inhibition of PD-1-PD-L1 interaction in cancers. Here authors show that anti-Tim3 therapy is working only in the presence of Il-2 co-stimulation, and the 2 necessary signals can be provided in the form of an anti-Tim3-Pro-Il2 construct, harboring modifications to the cytokine to resist the acidic tumour microenvironment.
- Xuhao Zhang
- Yu Gao
- Yang-Xin Fu